益佰制药(600594) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 501,480,776.32, representing a decrease of 12.43% compared to CNY 572,646,100.11 in the same period last year[5] - The net profit attributable to shareholders was a loss of CNY 9,385,719.46, an improvement from a loss of CNY 68,454,808.45 year-over-year[5] - The company's gross profit margin for Q1 2025 was approximately -2.36%, compared to -11.80% in Q1 2024[20] - Net profit for Q1 2025 was a loss of ¥11,427,837.53, compared to a loss of ¥71,411,782.78 in Q1 2024, indicating a significant improvement[21] Cash Flow - The net cash flow from operating activities decreased by 92.14%, amounting to CNY 7,526,352.13 compared to CNY 95,754,548.97 in the previous year[5] - Cash inflow from operating activities in Q1 2025 was ¥531,101,158.22, a decrease of 30.93% from ¥769,767,157.87 in Q1 2024[25] - Cash outflow from operating activities totaled $523,574,806.09, a decrease of 22.3% compared to $674,012,608.90 in the previous period[26] - Cash outflow from investing activities was $6,671,319.56, down 69.9% from $22,157,326.31 in the previous period[26] - Cash inflow from financing activities was $222,999,999.50, an increase of 50.5% from $148,000,000.00 in the previous period[26] - The ending balance of cash and cash equivalents was $455,074,557.37, down from $766,811,919.96, a decrease of 40.6%[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,994,902,808.73, down 2.56% from CNY 4,099,701,241.48 at the end of the previous year[6] - The company's current assets totaled RMB 1,685,288,665.38, down from RMB 1,750,026,094.89, indicating a decrease of about 3.71%[15] - Total liabilities decreased to RMB 1,400,220,344.81 from RMB 1,493,590,940.03, reflecting a decline of about 6.25%[16] - The company's non-current assets totaled RMB 2,309,614,143.35, down from RMB 2,349,675,146.59, indicating a decrease of about 1.70%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,054, with no preferred shareholders[10] - The total equity attributable to shareholders was ¥2,480,372,737.03, slightly down from ¥2,489,758,456.49[18] - The total equity remained stable at RMB 791,927,400.00, unchanged from the previous period[16] - The company has a share repurchase account holding 7,533,500 shares as of March 31, 2025[12] Cost Management - The company reported a significant reduction in costs and expenses, contributing to the improved net profit margin despite the overall revenue decline[8] - Total operating costs for Q1 2025 were ¥512,206,331.73, down 19.34% from ¥635,203,702.04 in Q1 2024[20] - Research and development expenses for Q1 2025 were ¥20,616,783.17, a decrease of 9.56% from ¥22,795,778.94 in Q1 2024[20] Strategic Focus - The company is focusing on cost management and operational efficiency to navigate the current market challenges and improve financial performance in the upcoming quarters[8]